Modeling a Human Hepatocellular Carcinoma Subset in Mice Through Coexpression of Met and Point-mutant β-catenin

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2016 Apr 21

PMID 27097116

Citations 79

Authors

Junyan Tao

Emily Xu

Yifei Zhao

Sucha Singh

Xiaolei Li

Gabrielle Couchy

Xin Chen

Jessica Zucman-Rossi

Maria Chikina

Satdarshan P S Monga

Affiliations

Soon will be listed here.

Abstract

Conclusion: We have identified cooperation of hMet and β-catenin activation in a subset of HCC patients and modeled this human disease in mice with a significant transcriptomic intersection; this model will provide novel insight into the biology of this tumor and allow us to evaluate novel therapies as a step toward precision medicine. (Hepatology 2016;64:1587-1605).

Citing Articles

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.

A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice.

Yang Y, Jn-Simon N, He Y, Sun C, Zhang P, Hu W Nat Aging. 2025; .

PMID: 39890936 DOI: 10.1038/s43587-025-00811-7.

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers.

Lehrich B, Monga S, Delgado E, Lehrich B, Delgado E, Yasaka T Res Sq. 2024; .

PMID: 39711542 PMC: 11661417. DOI: 10.21203/rs.3.rs-5494074/v1.

Cell-permeated peptide P-T3H2 inhibits malignancy on hepatocellular carcinoma through stabilizing HNF4α protein.

Wu S, Xiao M, Liu F, Hong H, Ding C, Zhang X Discov Oncol. 2024; 15(1):752.

PMID: 39638897 PMC: 11621286. DOI: 10.1007/s12672-024-01661-2.

METTL3-Mediated m6A Modification Regulates the Polycomb Repressive Complex 1 Components BMI1 and RNF2 in Hepatocellular Carcinoma Cells.

Chen W, Zhang J, Ma W, Liu N, Wu T Mol Cancer Res. 2024; 23(3):190-201.

PMID: 39625677 PMC: 11873720. DOI: 10.1158/1541-7786.MCR-24-0362.

References

Cieply B, Zeng G, Proverbs-Singh T, Geller D, Monga S . Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2008; 49(3):821-31. PMC: 2657345. DOI: 10.1002/hep.22695. View

Tardito S, Chiu M, Uggeri J, Zerbini A, Da Ros F, DallAsta V . L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets. 2011; 11(8):929-43. DOI: 10.2174/156800911797264725. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Armengol C, Cairo S, Fabre M, Buendia M . Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol. 2009; 43(2):265-70. DOI: 10.1016/j.biocel.2009.07.012. View

Eppig J, Blake J, Bult C, Kadin J, Richardson J . The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res. 2014; 43(Database issue):D726-36. PMC: 4384027. DOI: 10.1093/nar/gku967. View

Kaposi-Novak P, Lee J, Gomez-Quiroz L, Coulouarn C, Factor V, Thorgeirsson S . Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006; 116(6):1582-95. PMC: 1462944. DOI: 10.1172/JCI27236. View

Tward A, Jones K, Yant S, Cheung S, Fan S, Chen X . Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 2007; 104(37):14771-6. PMC: 1964540. DOI: 10.1073/pnas.0706578104. View

Lade A, Ranganathan S, Luo J, Monga S . Calpain induces N-terminal truncation of β-catenin in normal murine liver development: diagnostic implications in hepatoblastomas. J Biol Chem. 2012; 287(27):22789-98. PMC: 3391133. DOI: 10.1074/jbc.M112.378224. View

Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler S, Zeleznik-Le N . FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology. 2014; 61(1):214-26. PMC: 4280291. DOI: 10.1002/hep.27402. View

10.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

11.

Llovet J, Bruix J . Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48 Suppl 1:S20-37. DOI: 10.1016/j.jhep.2008.01.022. View

12.

Tao J, Calvisi D, Ranganathan S, Cigliano A, Zhou L, Singh S . Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014; 147(3):690-701. PMC: 4143445. DOI: 10.1053/j.gastro.2014.05.004. View

13.

Chen B, Chen W, Liang H, Liu H, Liang C, Zhi X . Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Mol Cancer Ther. 2015; 14(8):1805-15. PMC: 4866512. DOI: 10.1158/1535-7163.MCT-15-0029. View

14.

Delgado E, Okabe H, Preziosi M, Russell J, Alvarado T, Oertel M . Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J Hepatol. 2014; 62(2):380-7. PMC: 4300253. DOI: 10.1016/j.jhep.2014.10.021. View

15.

Patil M, Lee S, Macias E, Lam E, Xu C, Jones K . Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 2009; 69(1):253-61. PMC: 2628201. DOI: 10.1158/0008-5472.CAN-08-2514. View

16.

Giordano S, Columbano A . Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 2013; 60(2):442-52. DOI: 10.1016/j.jhep.2013.09.009. View

17.

Lafaro K, Demirjian A, Pawlik T . Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2014; 24(1):1-17. DOI: 10.1016/j.soc.2014.09.001. View

18.

Ryerson A, Eheman C, Altekruse S, Ward J, Jemal A, Sherman R . Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016; 122(9):1312-37. PMC: 4840031. DOI: 10.1002/cncr.29936. View

19.

Monga S . β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology. 2015; 148(7):1294-310. PMC: 4494085. DOI: 10.1053/j.gastro.2015.02.056. View

20.

Tan X, Behari J, Cieply B, Michalopoulos G, Monga S . Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology. 2006; 131(5):1561-72. DOI: 10.1053/j.gastro.2006.08.042. View